Antidiabetic Medications and Bladder Cancer Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

作者：Yi Rao, Shiqiu Meng, Evan Y. Yu, Yiming Chen, Remigius van Alebeek, Abdulmohsen H. Al‐Zalabani, Maurice P. Zeegers, Anke Wesselius · 发表于：Endocrine Practice · 年份：2025 · DOI：10.1016/j.eprac.2025.11.017 · 被引用次数：3 · 研究领域：Diabetes Treatment and Management、Metabolism, Diabetes, and Cancer、Chronic Kidney Disease and Diabetes

OBJECTIVE: The long-term safety of antidiabetic medications, particularly their potential association with bladder cancer (BC), remains a concern in type 2 diabetes mellitus (T2DM) management. METHODS: statistic. Subgroup analyses were conducted by drug class ((dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1Ras), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), thiazolidinedione). Publication bias was assessed via funnel plot. RESULTS: = 0.0%). For thiazolidinediones, only one study (pioglitazone) reported an OR of 2.37 (95% CI: 0.91-6.17), which was not statistically significant. Funnel plots suggested no obvious publication bias. CONCLUSIONS: This meta-analysis suggests that antidiabetic medications, including DPP-4i, GLP-1Ras, and SGLT-2i, are not significantly associated with BC risk in T2DM patients. These findings support the long-term safety profile of these medications.